Business Wire

The European Joint Programming Initiative on Neurodegenerative Disease Research (JPND) Organises Its International Scientific Meeting

26.11.2019 20:37:00 EET | Business Wire | Press release

Share

To disseminate up-to-date research achievements from 51 completed JPND-supported projects3 to relevant stakeholders, liaise, exchange knowledge and network, projects coordinators and their research consortiums, leading researchers and stakeholders will meet at the Royal Flemish Academy of Belgium for Sciences and the Arts in Brussels, Belgium, for a two-day symposium from 27 November to 28 November, 2019. This promises to provide a unique platform and opportunity for researchers to find out about one another’s work, communicate their latest research findings from their completed projects, build new relationships and enhance existing ones.

JPND Chair, Professor Philippe Amouyel says: “As the first and largest global collaborative research initiative established to tackle the growing challenge posed by neurodegenerative diseases, JPND’s ultimate goal is to improve the scientific understanding of neurodegenerative diseases, provide innovative approaches for their prevention, diagnosis and treatment, and ensure that individuals receive optimal care and quality of life at all stages of their illness. This symposium aims to facilitate knowledge sharing and communication between the different research groups and to disseminate up-to-date research achievements to relevant stakeholders.”

Project topics to be presented will range from Alzheimer’s to Parkinson’s diseases to rarer diseases such as Huntington’s disease, Amyotrophic Lateral Sclerosis, Prion disease, Spinal Muscular Atrophy and Spinocerebellar Ataxia .

Apart from 12 scientific sessions chaired and moderated by leading researchers in the field of neurodegenerative disease, the symposium will also delve into major questions of research via four thematic workshops, namely: Patient and Public Involvement in Research, Interactions with Industry, Knowledge Dissemination and Data Sharing.

Note to Editors:

JPND is committed to aligning and building upon national programmes to increase impact and effectiveness of research and to identify common goals that would benefit from joint action.

  • The origins and progression of neurodegenerative diseases
  • Disease mechanisms and models
  • Diagnosis, prognosis and disease definitions
  • Developing therapies, preventive strategies and interventions
  • Health and social care

JPND receives support from the European Commission.

Web: www.jpnd.eu
Twitter: @JPNDEurope
LinkedIn: https://www.linkedin.com/company/jpnd-joint-programme-neurodegenerative-disease-research

1 The EU Joint Programme – Neurodegenerative Disease Research (JPND) is the largest global research initiative aimed at tackling the challenge of neurodegenerative diseases. JPND aims to increase coordinated investment between participating countries in research aimed at finding causes, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases.
2 In 2015, JPND launched a joint transnational co-funded call in partnership with the European Commission under the ERA-NET Co-fund scheme in three JPND priority areas: Longitudinal Cohort Approaches, Advanced Experimental Models and Risk and Protective Factors
3 Research projects supported by the JPND calls of 2011 to 2013 and the JPco-fuND call of 2015

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press
Name: Karin YEO
Mobile: +33 07 8227 2887
Email: karin.yeo@jpnd.eu

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 14:00:00 EEST | Press release

NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac

Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 14:00:00 EEST | Press release

Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701144267/en/ Azalea Vision Co-founder and CTO Andrés Vásquez Quintero undergoing an on-eye evaluation of the ALMA smart contact lens. Beyond the funding, the award is a strong external endorsement of Azalea’s technology and long-term vision. Built on its proprietary smart contact lens platform, Azalea’s smart lens is designed to

Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 13:34:00 EEST | Press release

Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval of ChIQ™, we continue to strengthen the presence of our saypha® portfolio in the United States," said Andreas Prinz, Chief Executive Officer of Crom

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion1.7.2026 13:01:00 EEST | Press release

Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/ Dr. Hubert Scholze, Chief Business Officer, Rezon Bio As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution. His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated

CoStar Group Invests in Wikicasa, Italy’s Agent-Backed Real Estate Marketplace1.7.2026 13:00:00 EEST | Press release

CoStar Group, Inc. (NASDAQ: CSGP), a global leader in online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, today announced an investment in Wikicasa, Italy’s agent-backed real estate marketplace. The transaction will result in CoStar Group acquiring an approximately 30% stake in Wikicasa. Wikicasa’s shareholder base includes Italy’s leading real estate agencies - including Tecnocasa Group, Gabetti Group, RE/MAX Italy, and Tempocasa. Wikicasa.it is an agent-driven platform that brings together leading real estate professionals across Italy to deliver a high-quality, data-rich marketplace of over 600,000 listings, more than 100,000 of which are commercial. It provides consumers with comprehensive property listings while equipping agents with modern data and intelligence tools to market properties and connect with buyers, sellers, landlords and tenants. CoStar Group operates some of the world’s leading online residential and comme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye